Protagenic Therapeutics Inc.
06/29/2022 | Press release | Distributed by Public on 06/29/2022 07:16
Material Event - Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 29, 2022
PROTAGENIC THERAPEUTICS, INC.
(Exact name of Company as specified in its charter)
| Delaware | 001-12555 | 06-1390025 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 149 Fifth Avenue, Suite 500, New York, NY | 10010 | |
|
(Address of principal executive offices) |
(Zip Code) |
| 212-994-8200 | ||
|
(Company's telephone number, including area code) |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Protagenic Therapeutics, Inc. Common Stock | PTIX | Nasdaq | ||
| Protagenic Therapeutics, Inc. Common Stock Warrants | PTIXW | Nasdaq |
Item 8.01 Other Events.
The Company has updated its clinical development milestones.
The Company is in the process of completing the requirements to answer regulatory questions and begin the re-submission process in the US. In addition, the Company is submitting appropriate filing in Europe to commence a Phase I/IIa trial at a major CRO site in Germany which we anticipate will commence in Q3 2022.
The Company will provide further updates to its clinical development schedule as it becomes clearer.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROTAGENIC THERAPEUTICS, INC. | ||
| Date: June 29, 2022 | By: | /s/ Alexander K. Arrow |
| Name: | Alexander K. Arrow | |
| Title: | Chief Financial Officer |
| 3 |